Fasudil fOr redUcing elopemeNt and Spatial Disorientation (FOUND)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04793659|
Recruitment Status : Recruiting
First Posted : March 11, 2021
Last Update Posted : June 2, 2021
Fasudil, a Rho kinase inhibitor, is believed to reduce wandering behaviors of elopement and getting lost by improving spatial memory and navigation through improvements in hippocampal blood flow. Fasudil is non-sedating.
The aim of the study is to assess the effectiveness of oral fasudil in reducing wandering behaviors of elopement and/or getting lost in subjects with dementia. In addition, effects on wandering behaviors of excess movement and pacing, cognition, memory, neuropsychiatric symptomatology, caregiver/nursing staff burden, and the safety and tolerability of fasudil treatment will be assessed.
|Condition or disease||Intervention/treatment||Phase|
|Dementia||Drug: Oral Fasudil 90 mg/day Drug: Oral Fasudil 180 mg/day Drug: Oral Placebo||Phase 2|
The study population will consist of subjects with dementia and wandering behaviors of elopement and/or getting lost. While it is anticipated that most participants will be residing at home (with caregiver support), subjects may live in another setting such as a group home, an assisted living unit, or in a long-term care facility, provided that a caregiver, formal or informal, has sufficient contact with the subject to permit accurate completion of the necessary assessments.
Enrolled subjects will enter the Open-Label Phase and receive treatment with fasudil 90 mg/day (30 mg three times daily [tid]) for 6 weeks in Open-Label Period 1. Responders (i.e., subjects who improve 2 points or more on the GIW) will proceed to the Double-Blind Phase. Subjects in whom fasudil is well-tolerated (i.e. subjects with ≤ 2 drug-related AEs of mild intensity, no drug-related AEs of greater than mild intensity, and creatinine level of < 1.5 mg/dL at all times during the period) and who do not respond will enter Open-Label Period 2, and be dosed with fasudil 180 mg/day (60 mg tid) for 6 weeks. Responders will proceed to the Double-Blind Phase and non-responders will move to the final post-treatment visit. In the Double-Blind Phase, subjects will receive treatment with either placebo or the dose they responded to in the Open-Label Phase (90 mg/day or 180 mg/day) for 6 weeks (Double-Blind Period 1), following which treatment assignment will be crossed over for 6 weeks (Double-Blind Period 2). A final post-treatment visit will occur 14 days after the last dose of study drug. Visits may be performed by qualified healthcare professionals at home or other care setting, or at a doctor's office/clinic. Interviews may be performed by telephone and/or telemedicine as appropriate.
• The Global Impression of Wandering (GIW)
- Weekly Wandering Report - Community Version (WWR-C)
- The Revised Algase Wandering Scale - Community Version (RAWS-CV)
- The Mini Mental State Examination (MMSE)
- The Neuropsychiatric Inventory-Questionnaire (NPI-Q)
- The Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C)
- The Center for Neurological Study-Lability Scale (CNS-LS)
- The Zarit Burden Interview (ZBI)
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||Combined Open-Label and Double-Blind, Placebo-Controlled Crossover|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
Periods 1 and 2 of the open-label phase will be unblinded.
Periods 3 and 4 are double-blind crossover phases.
|Official Title:||A Phase 2a Combined Open-Label and Double-Blind, Placebo-Controlled Crossover Study Assessing the Effectiveness, Safety, and Tolerability of Oral Fasudil in Subjects With Dementia and Wandering Behaviors of Elopement and/or Getting Lost|
|Actual Study Start Date :||December 15, 2020|
|Estimated Primary Completion Date :||March 30, 2022|
|Estimated Study Completion Date :||March 30, 2022|
Experimental: Oral Fasudil 90 mg/day
Subjects will receive a daily dose of 90 mg Fasudil for 42 days (open-label period 1). After Period 1 is complete, if the subject is a responder to Fasudil 90 mg/day, they will be randomized to either Fasudil 90 mg/day or a placebo for 6 weeks (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
Drug: Oral Fasudil 90 mg/day
Drug: Oral Placebo
Experimental: Oral Fasudil 180 mg/day
If the subject is a not a responder in the open-label period 1 but tolerated Fasudil 90 mg/day, they will be escalated to Fasudil 180 mg/day (open-label period 2) for 42 days. If the subject is a responder to Fasudil 180 mg/day, they are randomized to either Fasudil 180 mg/day for 42 days or a placebo (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
Drug: Oral Fasudil 180 mg/day
Drug: Oral Placebo
Placebo Comparator: Oral Placebo
Placebo comparator arm to investigational drug (Fasudil 90 mg/day or 180 mg/day).
Drug: Oral Fasudil 90 mg/day
Drug: Oral Fasudil 180 mg/day
Drug: Oral Placebo
- Change in Global Impression of Wandering (GIW) after oral Fasudil vs placebo in the Double-Blind Phase [ Time Frame: Week 6 and Week 12 of the Double-Blind period ]The GIW is a variant of the 7-point Clinical Global Impression-Severity (CGI-S) scale and is used in FOUND specifically to obtain the investigator's overall assessment of severity of the subject's wandering behavior.
- Change in Weekly Wandering Report - Community Version (WWR-C) [ Time Frame: Weekly during the 12 weeks of the Double-Blind period ]The WWR-C is composed of targeted questions related to excess walking, spontaneous pacing, elopement, and wayfinding; it is designed to be assessed on a weekly basis by caregivers about subjects for whom they care. The WWR-C asks the caregiver to rate the subject's behavior for the previous week.
- Change in the Revised Algase Wandering Scale - Community Version (RAWS-CV) [ Time Frame: Week 6 and Week 12 of the Double-Blind period ]The RAWS-CV is a 40-item tool with 6 subscales to assess wandering behaviors (eloping behaviors, negative outcomes, mealtime impulsivity, persistent walking, repetitive walking, and spatial disorientation), and a total score scale.
- Change in Mini Mental State Examination (MMSE) [ Time Frame: Week 6 and Week 12 of the Double-Blind period ]The MMSE is a 30-point questionnaire that is used to measure cognitive impairment.
- Change in Neuropsychiatric Inventory-Questionnaire (NPI-Q) [ Time Frame: Week 6 and Week 12 of the Double-Blind period ]
The NPI-Q provides an assessment of dementia-related emotional behavioral symptomatology in routine clinical practice settings. Caregiver distress is also assessed.
The NPI-Q asks the assessor to rate the previous 30 days. At the Final Visit, the assessor will rate the NPI-Q for the 2-week period following the final dose. The scale is completed by the caregiver without input from the subject. All reasonable efforts should be made to ensure each NPI-Q for an individual subject is completed by the same caregiver to minimize inter-rater variability.
- Cohen-Mansfield Agitation Inventory - Community Version (CMAI-C) [ Time Frame: Week 6 and Week 12 of the Double-Blind period ]The CMAI-C is a 37-item scale to systematically assess agitation.
- Center for Neurological Study-Lability Scale (CNS-LS) [ Time Frame: Week 6 and Week 12 of the Double-Blind period ]The CNS-LS is a 7-item questionnaire to assess perceived frequency of pseudobulbar affect episodes.
- Zarit Burden Interview (ZBI) [ Time Frame: Week 6 and Week 12 of the Double-Blind period ]The ZBI is a 22-item scale to assess caregiver burden.
- Adverse Events (AEs) [ Time Frame: Through study completion, up to 26 weeks ]
- Serious Adverse Events (SAEs) [ Time Frame: Through study completion, up to 26 weeks ]
- Change in blood pressure [ Time Frame: Through study completion, up to 26 weeks ]
- Change in blood parameters [ Time Frame: Through study completion, up to 26 weeks ]Hematology: white blood cell count, hemoglobin, hematocrit, platelet count
- Change in blood chemistry [ Time Frame: Through study completion, up to 26 weeks ]Blood chemistry: glucose, sodium, potassium, bicarbonate, blood urea nitrogen, creatinine, cystatin c
- Change in liver function [ Time Frame: Through study completion, up to 26 weeks ]Liver function tests: albumin, total bilirubin, direct bilirubin, ALP, AST, ALT, gamma glutamyl transferase, lactate dehydrogenase
- Change in urine contents [ Time Frame: Through study completion, up to 26 weeks ]Urinalysis (occult blood, protein)
- Change in heart rhythm [ Time Frame: Through study completion, up to 26 weeks ]12-lead Electrocardiogram (ECG) will be used to obtain a record of cardiac activity
- Change in body weight [ Time Frame: Through study completion, up to 26 weeks ]
- Change in body temperature [ Time Frame: Through study completion, up to 26 weeks ]
- Change in respiratory rate [ Time Frame: Through study completion, up to 26 weeks ]
- Columbia Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Through study completion, up to 26 weeks ]
The C-SSRS is an assessment used to identify immediate risk of suicide, and is completed following the patient interview, review of medical record(s) and/or consultation with family members and/or other professionals. While the C-SSRS is a detailed interview, the full interview is needed only if the initial screening questions about suicidal ideation and behavior are positive.
In subjects with severe cognitive impairment, i.e., so substantial as to interfere with an understanding of the concept of suicide, the C-SSRS may be omitted.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04793659
|Contact: Ann Tunstallemail@example.com|
|Contact: Ibrahim Mian, MDfirstname.lastname@example.org|
|United States, Connecticut|
|New England Institute for Clinical Research||Recruiting|
|Stamford, Connecticut, United States, 06905|
|Contact: Nicole Jelic 203-914-1900 email@example.com|
|Principal Investigator: Peter J. McAllister, MD|
|United States, Florida|
|Accel Research Sites||Recruiting|
|Lakeland, Florida, United States, 33803|
|Contact: Diana Holmes 863-940-2087 firstname.lastname@example.org|
|Principal Investigator: James Andersen, MD|
|Lakes Research, LLC.||Recruiting|
|Miami Lakes, Florida, United States, 33014|
|Contact: Yami Sanchez 786-362-5763 email@example.com|
|Principal Investigator: Jose V. Perez, DO|
|Accel Research Sites - Tampa Clinical Research Unit||Recruiting|
|Tampa, Florida, United States, 33634|
|Contact: Gail McDonnell 813-877-8839 firstname.lastname@example.org|
|Principal Investigator: Deborah A. Burke, MD|
|United States, New Jersey|
|Bio Behavioral Health||Recruiting|
|Toms River, New Jersey, United States, 08755|
|Contact: Dawn Arnone 732-244-2299 email@example.com|
|Principal Investigator: Ashok K. Patel, MD|
|United States, New Mexico|
|Albuquerque Neuroscience Inc.||Recruiting|
|Albuquerque, New Mexico, United States, 87109|
|Contact: Anderson Riddle 505-848-3773 firstname.lastname@example.org|
|Principal Investigator: Glenn M. Dempsey, MD|
|United States, Texas|
|Clinical Trials of Texas, Inc.||Recruiting|
|San Antonio, Texas, United States, 78229|
|Contact: Nathan Cortez 210-846-2164 email@example.com|
|Principal Investigator: Martha E. Leatherman, MD|
|United States, Virginia|
|Fairfax, Virginia, United States, 22031|
|Contact: Monica Bland 703-520-9703 firstname.lastname@example.org|
|Principal Investigator: Raymond S. Turner, MD|
|Eastern Virginia Medical School||Recruiting|
|Norfolk, Virginia, United States, 23507|
|Contact: David Elkins 757-446-5285 ElkinsDE@evms.edu|
|Principal Investigator: Hamid Okhravi, MD|
|Australia, South Australia|
|Modbury, South Australia, Australia, 5092|
|Contact: Greer Dymmott 08 7321 4248|
|Principal Investigator: Sally Johns|
|Geelong, Victoria, Australia, 3220|
|Contact: Lea Del Rio 03 5223 1093|
|Principal Investigator: Alaistar Mander|
|Shepparton, Victoria, Australia, 3630|
|Contact: Ainsley Robinson 03 5832 3080|
|Principal Investigator: Arup Bhattacharya|
|Northeast Health Wangaratta||Recruiting|
|Wangaratta, Victoria, Australia, 3677|
|Contact: Nicole Humphreys 03 5722 0111|
|Principal Investigator: Lakshmi Dhakal|
|Australia, Western Australia|
|Neurodegenerative Disorders Research||Recruiting|
|West Perth, Western Australia, Australia, 6005|
|Contact: Cheryl MacFarlane 618-6317-9427|
|Principal Investigator: PK Panegyres|